ORGO Organogenesis
- 3.870
- -0.030-0.77%
- 3.900
- +0.030+0.78%
Organogenesis News
Organogenesis Announces Plans To Expand Manufacturing Capacity With A Long-Term Lease A Biomanufacturing Facility Located At 100 Technology Way In Smithfield, Rhode Island
US Manufacturing Index Rises To 43, Highest Since 2020
Organogenesis Holdings Inc. Applauds CMS Decision on Coverage for Skin Substitute Products for Diabetic and Venous Ulcers
Organogenesis 'Commends' Final Local Coverage Determinations
Press Release: Organogenesis Commends Final LCDs
Morgan Stanley Sticks to Their Hold Rating for Organogenesis Holdings (ORGO)
Cantor Fitzgerald Maintains Organogenesis(ORGO.US) With Buy Rating, Raises Target Price to $3.8
Paymentus Posts Better-Than-Expected Earnings, Joins Dave, Honest Company, Natera, CAVA Group And Other Big Stocks Moving Higher On Wednesday
Organogenesis Holdings Secures $130M Investment for Growth
BTIG Maintains Organogenesis(ORGO.US) With Buy Rating, Maintains Target Price $6
Organogenesis Reports Robust Third Quarter Growth
Organogenesis Holdings, Inc. (ORGO) Q3 2024 Earnings Call Transcript Summary
Organogenesis (ORGO) Q3 2024 Earnings Call Transcript
Organogenesis | 8-K: Organogenesis Holdings Inc. Reports Third Quarter 2024 Financial Results
Organogenesis Hldgs Q3 2024 Adj. EPS $0.10 Beats $(0.01) Estimate, Sales $115.177M Beat $108.833M Estimate
Organogenesis | 10-Q: Q3 2024 Earnings Report
Express News | Organogenesis Hldgs Raises FY2024 Sales Guidance From $445.00M-470.00M to $445.00M-480.00M
Express News | Organogenesis Outlook FY Adjusted Ebitda USD 31.7-47.4 Million
Express News | Organogenesis Q3 Operating Income USD 6.2 Million
Press Release: Organogenesis Holdings Inc. Reports Third Quarter 2024 Financial Results
Analysis
Price Target
No Data
No Data